This case represents one of the longest reported durations of response to Olaparib in an EGFR and BRCA2 co-mutated NSCLC patient with leptomeningeal metastases, underscoring the potential of PARP inhibitors in combination with targeted therapy and intrathecal chemotherapy for managing this challenging patient population. This evidence concerns the gene BRCA2 and non-small cell lung carcinoma.